help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HERTING, E.
Right arrow Articles by ROBERTSON, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HERTING, E.
Right arrow Articles by ROBERTSON, B.

Am. J. Respir. Crit. Care Med., Volume 159, Number 6, June 1999, 1862-1867

Combined Treatment with Surfactant and Specific Immunoglobulin Reduces Bacterial Proliferation in Experimental Neonatal Group B Streptococcal Pneumonia

EGBERT HERTING, XIAOZHUANG GAN, PETRA RAUPRICH, CONNIE JARSTRAND, and BENGT ROBERTSON

Department of Pediatrics, University of Göttingen, Göttingen, Germany; Division for Experimental Perinatal Pathology, Department of Woman and Child Health, Karolinska Institute, Stockholm; and Division of Clinical and Oral Bacteriology, Department of Immunology, Pathology, and Infectious Diseases, Karolinska Institute, Huddinge Hospital, Stockholm, Sweden

Neonates suffering from group B streptococcal (GBS) pneumonia often lack type-specific opsonizing antibodies. We studied the influence of combined intratracheal treatment with surfactant and a specific antibacterial polyclonal antibody (IgG fraction) on bacterial proliferation and lung function in an animal model of GBS pneumonia. Near-term newborn rabbits received an intratracheal injection of either the specific IgG antibody, nonspecific IgG, surfactant, a mixture of surfactant and the antibody, or 0.9% saline. At 30 min the rabbits were infected with a standard dose (108) of the encapsulated GBS strain 090 Ia. After 5 h of mechanical ventilation the mean estimated increase in bacterial number in lung homogenate (log10 colonies/g) was 0.76 in the antibody group, 0.92 in the nonspecific IgG group, 0.55 in the surfactant group, and 1.29 in the saline group. A mean decrease in bacterial number (-0.05) was observed in the group that received combined treatment with surfactant and antibody (p < 0.05 versus all other groups). Lung-thorax compliance was significantly higher in both groups of surfactant-treated animals compared with saline or IgG treatment. We conclude that in experimental neonatal GBS pneumonia combined treatment with surfactant and a specific immunoglobulin against GBS reduced bacterial proliferation more effectively than either treatment alone.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
A. van Kaam, R. Lachmann, F. van Iwaarden, J. Haitsma, B. Lachmann, A. De Jaegere, A. Noorduyn, J. Kok, and E. Herting
Should We Start Considering Surfactant for Atelectasis?
Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 141 - 142.
[Full Text] [PDF]

Home page
 PediatricsHome page
E. Herting, O. Gefeller, M. Land, L. van Sonderen, K. Harms, B. Robertson, and Members of the Collaborative European Multicenter
Surfactant Treatment of Neonates With Respiratory Failure and Group B Streptococcal Infection
Pediatrics, November 1, 2000; 106(5): 957 - 964.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society